Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Chief Financial Officer | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,378 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 6,675 · Balance 159,378 F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 6,675 | $19.11 | $127,579.94 |
DisclosureSEC source: 0002048588-26-000013 · form4-09032026_060903.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,378 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 20:46 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,896 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-26-000009 · form4-06302026_080605.xml · derivative · entry 6 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,817 Underlying: Common Stock · 4,896 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 20:46 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,896 | $17.03 | $83,380.84 |
DisclosureSEC source: 0002048588-26-000009 · form4-06302026_080605.xml · nonDerivative · entry 4 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,931 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F3 · price: The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 20:46 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 4,896 | $5.10 | $24,969.60 |
DisclosureSEC source: 0002048588-26-000009 · form4-06302026_080605.xml · nonDerivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 22:44 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,896 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-26-000010 · form4a-07022026_100725.xml · derivative · entry 6 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,695 Underlying: Common Stock · 4,896 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. F1 · balance_after: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 22:44 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,896 | $17.03 | $83,380.84 |
DisclosureSEC source: 0002048588-26-000010 · form4a-07022026_100725.xml · nonDerivative · entry 4 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,053 F2 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F4 · price: The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · balance_after: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 22:44 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 4,896 | $5.10 | $24,969.60 |
DisclosureSEC source: 0002048588-26-000010 · form4a-07022026_100725.xml · nonDerivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:46 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,982 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-26-000009 · form4-06302026_080605.xml · derivative · entry 5 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,713 Underlying: Common Stock · 4,982 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:46 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 5,104 | $17.05 | $87,006.36 |
DisclosureSEC source: 0002048588-26-000009 · form4-06302026_080605.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,931 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:46 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 4,982 | $5.10 | $25,408.20 |
DisclosureSEC source: 0002048588-26-000009 · form4-06302026_080605.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2026 Filed Jul 2, 2026 22:44 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,104 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-26-000010 · form4a-07022026_100725.xml · derivative · entry 5 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,591 Underlying: Common Stock · 5,104 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. F5 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. F1 · derivative.underlying_shares: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. F1 · balance_after: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Read SEC document |
| June 26, 2026 Filed Jul 2, 2026 22:44 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 5,104 | $17.05 | $87,006.36 |
DisclosureSEC source: 0002048588-26-000010 · form4a-07022026_100725.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,053 F2 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F3 · price: The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · balance_after: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Read SEC document |
| June 26, 2026 Filed Jul 2, 2026 22:44 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 5,104 | $5.10 | $26,030.40 |
DisclosureSEC source: 0002048588-26-000010 · form4a-07022026_100725.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. F1 · balance_after: This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 6,676 | $12.61 | $84,165.00 |
DisclosureSEC source: 0002048588-26-000008 · form4-06032026_060603.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,053 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,428 | $12.36 | $17,652.36 |
DisclosureSEC source: 0002048588-26-000003 · form4-03032026_060304.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,729 F2 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 70,831 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002048588-26-000003 · form4-03032026_060304.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,831 Underlying: Common Stock · 70,831 shares Expires 2036-02-26 F4 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 131,543 | $0.00 | $0.00 |
DisclosureSEC source: 0002048588-26-000003 · form4-03032026_060304.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,157 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| February 27, 2026 Filed Mar 13, 2026 20:15 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 110,342 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002048588-26-000005 · form4a-03132026_040304.xml · derivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,342 Underlying: Common Stock · 110,342 shares Expires 2036-02-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:03 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-26-000002 · form4-01052026_110150.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,695 Underlying: Common Stock · 20,000 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:03 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 20,000 | $29.53 | $590,680.00 |
DisclosureSEC source: 0002048588-26-000002 · form4-01052026_110150.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,614 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $29.534002 and the range of prices were between $29.09 and $30.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:03 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 20,000 | $5.10 | $102,000.00 |
DisclosureSEC source: 0002048588-26-000002 · form4-01052026_110150.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:20 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,427 | $29.34 | $41,862.33 |
DisclosureSEC source: 0002048588-25-000008 · form4-12042025_041203.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,614 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,982 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-25-000004 · form4-10072025_041001.xml · derivative · entry 4 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,695 Underlying: Common Stock · 4,982 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,154 | $22.28 | $25,708.58 |
DisclosureSEC source: 0002048588-25-000004 · form4-10072025_041001.xml · nonDerivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,041 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F3 · price: The weighted average sale price for the transaction reported was $22.2778 and the range of prices were between $22.0438 and $22..47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 3,828 | $21.52 | $82,367.84 |
DisclosureSEC source: 0002048588-25-000004 · form4-10072025_041001.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,195 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $21.5172 and the range of prices were between $21.04 and $22.0144. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 4,982 | $5.10 | $25,408.20 |
DisclosureSEC source: 0002048588-25-000004 · form4-10072025_041001.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:31 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,018 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0002048588-25-000003 · form4-10032025_081044.xml · derivative · entry 4 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,677 Underlying: Common Stock · 15,018 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:31 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 100 | $21.08 | $2,108.00 |
DisclosureSEC source: 0002048588-25-000003 · form4-10032025_081044.xml · nonDerivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,041 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:31 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 14,918 | $20.76 | $309,697.68 |
DisclosureSEC source: 0002048588-25-000003 · form4-10032025_081044.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,141 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $20.76 and the range of prices were between $20.03 and $21.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:31 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 15,018 | $5.10 | $76,591.80 |
DisclosureSEC source: 0002048588-25-000003 · form4-10032025_081044.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:12 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,900 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-023969 · form4-09092025_080923.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,695 Underlying: Common Stock · 9,900 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:12 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 9,900 | $21.13 | $209,151.36 |
DisclosureSEC source: 0001415889-25-023969 · form4-09092025_080923.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,041 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $21.126480 and the range of prices were between $21.00 and $21.2933. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:12 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 9,900 | $5.10 | $50,490.00 |
DisclosureSEC source: 0001415889-25-023969 · form4-09092025_080923.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-023898 · form4-09082025_060901.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,595 Underlying: Common Stock · 100 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 100 | $21.00 | $2,100.00 |
DisclosureSEC source: 0001415889-25-023898 · form4-09082025_060901.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,041 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 100 | $5.10 | $510.00 |
DisclosureSEC source: 0001415889-25-023898 · form4-09082025_060901.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,462 | $18.86 | $27,578.00 |
DisclosureSEC source: 0001415889-25-023742 · form4-09042025_060901.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,041 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:29 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,413 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-023023 · form4-08262025_080841.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,695 Underlying: Common Stock · 4,413 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:29 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,413 | $17.01 | $75,082.78 |
DisclosureSEC source: 0001415889-25-023023 · form4-08262025_080841.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,503 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $17.0140 and the range of prices were between $17.00 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:29 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 4,413 | $5.10 | $22,506.30 |
DisclosureSEC source: 0001415889-25-023023 · form4-08262025_080841.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,587 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-022539 · form4-08202025_090801.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,108 Underlying: Common Stock · 5,587 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 5,587 | $17.03 | $95,171.75 |
DisclosureSEC source: 0001415889-25-022539 · form4-08202025_090801.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,503 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. F2 · price: The weighted average sale price for the transaction reported was $17.034505 and the range of prices were between $17.00 and $17.095. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | Exercise / conversionCommon Stock | 5,587 | $5.10 | $28,493.70 |
DisclosureSEC source: 0001415889-25-022539 · form4-08202025_090801.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 136 | $18.69 | $2,541.98 |
DisclosureSEC source: 0001415889-25-015667 · form4-06042025_070608.xml · nonDerivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,503 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F4 · price: The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 951 | $18.15 | $17,259.60 |
DisclosureSEC source: 0001415889-25-015667 · form4-06042025_070608.xml · nonDerivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,639 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 410 | $17.03 | $6,981.48 |
DisclosureSEC source: 0001415889-25-015667 · form4-06042025_070608.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,590 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 71,000 | $0.00 Strike: $19.91 | $0.00 |
DisclosureSEC source: 0001415889-25-006231 · form4-03032025_050304.xml · derivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2035-02-26 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from February 27, 2025. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006231 · form4-03032025_050304.xml · nonDerivative · entry 1 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 186,203 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002816 · form4-02032025_080204.xml · derivative · entry 3 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,203 Underlying: Common Stock · 186,203 shares Expires 2035-01-28 F4 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 109,695 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-002816 · form4-02032025_080204.xml · derivative · entry 2 Feider Stephen · CIK 0002048588 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,695 Underlying: Common Stock · 109,695 shares Expires 2033-09-13 F3 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.